Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
